MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF

• US 20090155275A1
• Filed: 07/30/2008
• Published: 06/18/2009
• Est. Priority Date: 07/31/2007
• Status: Abandoned Application

• Current Assignee: Medimmune LLC (Astrazeneca PLC)
• Original Assignee: Medimmune LLC (Astrazeneca PLC)
• Inventors: HAY, Carl, GAO, Changshou, DIMASI, Nazzareno, WU, Herren
• Application Number:
  US12/182,975
• Publication Number:
  US 20090155275A1
• Time in Patent Office: Days
• US Class Current: 424/136.100
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/522 CH1 domain
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/64 comprising a combination of variable region and constant region components

Abstract

The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.

Claims

1-139. -139. (canceled)

140. An isolated multispecific epitope binding protein comprising a first and a second polypeptide chain, wherein the first chain comprises a member selected from the group consisting of:

a. one or more Fc regions linked N-terminal to at least one epitope binding domain (EBD);

b. one or more Fc regions linked C-terminal to at least one EBD;

c. at least three or more EBDs;

d. at least one or more Fc regions;

e. at least one or more CH1 domains; and

f. at least one or more Cκ

or Cλ

domains.

142. The protein of any of claims 140-141, wherein the protein is capable of binding at least two, at least three, at least four, at least five, at least six epitopes concurrently upon administration to a mammal or in vitro.

143. The protein of any one of claims 140-141, wherein at least one EBD is selected from the group consisting of an scFv, a single chain single chain diabody, an antibody mimetic, and an antibody variable domain.

144. The protein of claim 143, wherein said antibody mimetic is selected from the group consisting of a minibody, a maxybody, an avimer, an Fn3 based protein scaffold, an ankrin repeat, a VASP polypeptide, an avian pancreatic polypeptide (aPP), a Tetranectin, an affililin, a knottin, an SH3, a PDZ domain, a protein A domain, a lipocalin, a transferrin, and a kunitz domains.

145. The protein of claim 140, wherein said protein has the functional activity of depleting a cell population, inhibiting or reducing proliferation of a cell population, inhibiting or reducing secretion of inflammatory mediators from a cell population, inhibiting or reducing secretion of cytoplasmic granules from a cell population, wherein said cell population is selected from the group consisting of:

T cells, B cells, mast cells, eosinophils, basophils, neutrophils, dendritic cells, monocytes, macrophages, and tumor cells.

146. A method of making the protein of any of claims 140-141, wherein said method comprises a scalable process for making said protein wherein said scalable process results in a production efficiency of said protein from about 10 mg/L to about 300 mg/L and said protein retains at least one functional activity.

147. The method of claim 146, wherein said protein produced from said process exhibits an aggregation level of no more than 5% by weight of protein as measured by HPSEC.

148. A method of ameliorating, treating or preventing a disease or disorder or a symptom thereof by administering a sterile formulation of a therapeutically effective amount of the protein of any of claims 140-141 to a patient in need thereof, wherein said disease or disorder is selected from the group consisting of:

a. cancer;

b. inflammatory or autoimmune disease; and

c. infectious disease.

149. The method of claim 148 wherein the type of cancer is selected from the group consisting of cancer of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, colorectal, stomach, spleen, renal, skeletal muscle, subcutaneous tissue, metastatic melanoma, endometrial, prostate, breast, ovaries, testicles, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain or central nervous system.

150. The method of claim 148 wherein the type of inflammatory or autoimmune disease is selected from the group consisting of rheumatoid arthritis, SLE, or Sjogren'"'"'s syndrome.

141. An isolated multispecific epitope binding protein comprising a first and a second polypeptide chain, wherein the second chain comprises a member selected from the group consisting of:

a. one or more Cκ

or Cλ

regions linked N-terminal to at least one EBD;

b. one or more Cκ

or Cλ

regions linked C-terminal to at least one EBD;

c. at least three or more EBDs;

d. at least three or more EBDs and at least one or more Cκ

or Cλ

regions;

e. at least two or more EBDs, at least one antibody variable region, and a Cκ

or Cλ

region;

f. at least one or more CH1 domains; and

g. at least one or more Cκ

or Cλ

domains.